Adoptive immunotherapy of cancer with polyclonal, 10(8)-fold hyperexpanded, CD4(+ )and CD8(+ )T cells

T cell-mediated cancer immunotherapy is dose dependent and optimally requires participation of antigen-specific CD4(+ )and CD8(+ )T cells. Here, we isolated tumor-sensitized T cells and activated them in vitro using conditions that led to greater than 10(8)-fold numerical hyperexpansion of either the CD4(+ )or CD8(+ )subset while retaining their capacity for in vivo therapeutic efficacy. Murine tumor-draining lymph node (TDLN) cells were segregated to purify the CD62L(low )subset, or the CD4(+ )subset thereof. Cells were then propagated through multiple cycles of anti-CD3 activation with IL-2 + IL-7 for the CD8(+ )subset, or IL-7 + IL-23 for the CD4(+ )subset. A broad repertoire of TCR Vβ families was maintained throughout hyperexpansion, which was similar to the starting population. Adoptive transfer of hyper-expanded CD8(+ )T cells eliminated established pulmonary metastases, in an immunologically specific fashion without the requirement for adjunct IL-2. Hyper-expanded CD4(+ )T cells cured established tumors in intracranial or subcutaneous sites that were not susceptible to CD8(+ )T cells alone. Because accessibility and antigen presentation within metastases varies according to anatomic site, maintenance of a broad repertoire of both CD4(+ )and CD8(+ )T effector cells will augment the overall systemic efficacy of adoptive immunotherapy.